Kidney Care Models

Virtual kidney care vendors faced renewed scrutiny after PHTI found limited evidence that these solutions slow CKD progression or reduce costs, sharpening the burden of proof for Kidney Care Choices, MA risk-bearing groups, ACOs, and specialty kidney partners that rely on digital CKD management to justify shared-savings economics (PHTI/Fierce Healthcare). At the same time, Strive Health is positioning its AI-enabled care model around fragmented data integration, clinician workflow embedding, and provider-led decision support—signaling that kidney VBC players are shifting from “virtual care access” narratives toward measurable operational infrastructure for population health management (Strive Health). A new FDA approval for finerenone in CKD with type 1 diabetes adds a therapeutic lever, but the week’s core tension is whether kidney care models can translate tools, drugs, and AI into demonstrable reductions in progression, dialysis starts, total cost of care, and avoidable utilization.